The providers we cover, and what we checked.
How big the compounded-GLP-1 telehealth market is, what the FDA changed, and the providers we cover — with the honest read on each. Independent: placement and scoring are never for sale.
The providers we cover.
Listed alphabetically — name, what kind of provider it is, how broad its menu is, and who it's best for. No prices, no rankings here; those live in each provider's full review and in the comparison pages.
| Provider | Breadth | Best for |
|---|---|---|
| AgelessRx Premium DTC (longevity) | Rapamycin + metformin + LDN + NAD+ + peptides | Patients who want off-label longevity prescribing from a platform that publishes its own research — and who will check what that research actually is |
| Defy Medical Physician-led clinic | TRT + HRT + peptides + GLP-1 + labs | Patients who want a clinic with premises and a fifteen-year history rather than a storefront, and can absorb unpublished consultation and lab costs |
| Eden Multi-category DTC | Compounded GLP-1 at one price for every dose + branded GLP-1, sermorelin, NAD+ and glutathione on a membership | Patients who want compounded semaglutide or tirzepatide at one monthly price that does not rise with the dose, from a company that runs its own pharmacy |
| Henry Meds Budget DTC (compounded) | GLP-1 + phentermine + TRT + HRT + ED | Compounded GLP-1 with deep prepay discounts from a high-volume operator (12k+ Trustpilot reviews) |
| Hims Premium DTC (public) | Branded GLP-1 + sexual + hair + mental + labs | Patients who want FDA-approved branded GLP-1 via manufacturer-direct programs, with a credentialed advisory board |
| Invigor Medical Multi-category DTC | Peptides + GLP-1 + TRT + sexual wellness | Buyers who already know the molecule and dose they want, since no product page on the site states either |
| Lavender Sky Health Budget DTC (compounded) | Compounded + branded GLP-1, priced per pharmacy | Patients who want to choose the compounding pharmacy by name and price, and whose state leaves them more than one option |
| Live Vital Multi-category DTC | Compounded GLP-1 + peptide protocols + NAD+ and glutathione, priced by the month without a dose | Patients who want a named physician and a monthly figure, and who will ask for the dose, the pharmacy and the refund terms before paying |
| MadeMed Budget DTC (compounded) | Compounded GLP-1 + sermorelin + NAD+ + glutathione + GHK-Cu + hormones + hair | Patients who want the strength printed beside most prices and no first-month teaser — and who are happy to choose between 30-, 90- and 360-day billing |
| Maximus Premium DTC (men's hormone) | Testosterone (4 formats) + GLP-1 + peptides | Optimization-focused men committed to testosterone protocols, with advisers Maximus describes as academic urologists |
| Mochi Health Budget DTC (compounded) | GLP-1 marketplace + skincare / hair / mental / longevity | Patients who want provider and pharmacy choice in a membership marketplace |
| PeterMD Multi-category DTC | TRT + GLP-1 + wide peptide catalogue | Buyers who already know the exact product they want and accept that no legal entity, prescriber or Trustpilot profile stands behind the site |
| Ro Premium DTC (private) | Branded GLP-1 + sexual + hair + derm + fertility | Patients who want a broad branded DTC menu with an insurance-check option |
| RxPepsDirect Multi-category DTC | Seventy-odd compounded products, each priced by the vial with its strength, plus a $39 review per order | Patients who know their compound and dose, want a per-milligram price and lot-level sterility reports, and will check each item against FDA's lists first |
| Strut Health Budget DTC (compounded) | Compounded GLP-1 + sexual + hair + skin | Patients comfortable with an unnamed compounding pharmacy and a Feb 2026 FDA warning letter on the public record |
| TeleZenMD Multi-category DTC | Wide peptide menu | Patients who want a system — breadth, behavioral program, named physicians |
| TrimRx Budget DTC (compounded) | GLP-1 only (compounded sema + tirz) | Price-driven patients aware of the documented billing-complaint pattern |
No providers match these filters.
How big, how fast, and the scope caveat.
The honest answer is that GLP-1 and broader obesity medicines are the only segment we can size from primary sources — public-company filings and IQVIA's commercial-intelligence reports. The wider "peptide therapeutics" market (insulin, oncology peptides, anti-infectives) is covered by commercial market-research firms whose estimates diverge by more than 2× across the same year; we treat those as a noisy range, not authority.
What the primary sources show. IQVIA's ForecastLink[1] projects the global obesity-medicines market at about $66B in 2025, rising to $92B in 2026 and $105–200B by 2027+. The engine is the GLP-1 / GIP class. Eli Lilly's Mounjaro + Zepbound (tirzepatide) together generated $36.5B in 2025 — Mounjaro $23.0B and Zepbound $13.5B for the full year, per Lilly's Q4 2025 financial results[4]; IQVIA reports the pair surpassed Merck's Keytruda[2] as the world's best-selling medicine. Novo Nordisk's semaglutide products[5] (Ozempic + Wegovy) added roughly $25B USD in 2024 — Ozempic ~$17B and Wegovy ~$8B, with Wegovy revenue roughly doubling year-over-year as obesity uptake accelerated.
The telehealth / compounded niche is what PeptideWellness actually covers — narrower, newer, and not cleanly sized by the big reports. The signals of its scale: Hims & Hers alone projected $2.7–2.9B revenue for 2026[6] in its Q4 2025 SEC filing; a peer-reviewed AJMC analysis[7] of a US commercial claims database (28.2M enrollees in 2018, 23.0M in 2023) found GLP-1 RA users grew from 745 per 100,000 enrollees in 2018 to 3,572 per 100,000 in 2023 — and within that pool, the share without a diabetes diagnosis roughly tripled, from 11% to 34%, as off-label weight-loss use accelerated; and IQVIA tracks compounded GLP-1 as a distinct "non-traditional channel"[8] reshaping pharma distribution.
Scope caveat, stated plainly. Even the primary sources above are pharma-centric — organised around clinical indications. They map well onto GLP-1 weight loss and poorly onto our other categories — recovery, longevity, cognitive, skin/hair. Most of those circulate as compounded or research-grade peptides outside the formal therapeutics market, so reliable top-down sizing for them barely exists. Demand there is real but under-measured.
What changed, and why it matters.
For most of 2023–2024, "compounded semaglutide" was a shortage-era workaround that turned into a category. Telehealth brands built funnels around it, and prices fell fast. Then the legal basis moved out from under it.
The FDA delisted tirzepatide[9] from its shortage list in December 2024 and semaglutide in February 2025. The 503A grace period ended 22 April 2025; the 503B grace period ended 22 May 2025. The agency has publicly flagged adverse-event reports tied to compounded versions[10] — by 31 July 2025, external analyses of FAERS data[12] counted 1,150+ events including 17 reported deaths, though FDA itself notes that compounded-pharmacy events are systematically under-reported (most state-licensed compounders are not required to file with FAERS). On 30 April 2026 the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List[11] permanently, with public comment open until 29 June 2026.
The practical effect: mass-compounding of sema/tirz no longer rests on a shortage justification. What remains is narrow, patient-specific 503A compounding; it's bulk 503B sema/tirz that loses its footing first. The branded drugs (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda) remain the FDA-approved reference point that compounded versions are modeled on.
Providers have responded in three ways — and that response is the clearest way to read the market:
- 01 Retreat from compounded GLP-1 toward brand-name drugs and insurance billing (Hims pulled compounded tirzepatide entirely; see StatNews coverage of the Q4 2025 earnings call[13]).
- 02 Hold the compounded line under patient-specific pathways, competing on access (TrimRx, Maximus, Mochi).
- 03 Broaden beyond GLP-1 into the wider peptide and hormone categories — recovery, longevity, sexual health, skin and hair (TeleZenMD is the clearest example).
Worth flagging: legal status here is dynamic. Every provider page says so, and dates its claims.
The providers, in aggregate.
The notes below describe the providers we cover qualitatively; prices and head-to-head verdicts are left to the individual reviews and comparisons.
Payment model
Almost entirely cash-pay direct-to-consumer. Insurance involvement is limited across the category.
Category breadth
Breadth varies across three groups. TrimRx and Mochi are GLP-1-only. Hims, Ro, Henry Meds, and Maximus add some adjacent products (men's health, recovery, biohacking). TeleZenMD has a wide menu — recovery, longevity, sexual health, skin/hair, and hormones alongside GLP-1.
How they tier
A premium DTC band (Hims, Ro, Henry Meds) sells brand polish, app experience, and pharmacy depth. A budget DTC band (TrimRx, Maximus, Mochi) competes on sticker price and on niche positioning — Maximus, for example, on microdose and stacking optionality. TeleZenMD doesn't sit cleanly in either tier: a multi-category model with a mid-market price band.
Commitment
Most plans are month-to-month. Hims ties its headline rate to a six-month commitment. Annual or multi-month prepayment plans, where offered, buy the lowest monthly-equivalent rate in exchange for paying upfront.
Tirzepatide
Most of the set still offers compounded tirzepatide. Hims is the notable exit (discontinued late 2025 / early 2026). Regulation-sensitive — recheck after 29 June 2026.
Who makes the medication
Of the 17 providers we cover, 6 name the pharmacy that fills a prescription on their public pages, 2 names only its own, and 9 name none. The pharmacy register lists every one, with the page each answer comes from.
Not shown here
Provider-by-provider market share or patient volume. The companies don't publish those numbers, and no independent tracker aggregates them at this level. We don't repeat figures we can't source.
Sources cited above.
Market sizing — the primary sources we anchor on
- IQVIA, The outlook for obesity from 2026 to 2030 — global obesity-medicines market $66B (2025) → $92B (2026) → $105–200B (2027+), from IQVIA ForecastLink — iqvia.com
- IQVIA, Outlook for Obesity in 2026: From Consolidation to Acceleration — Mounjaro + Zepbound surpassed Keytruda as world's best-selling medicine in 2025 — iqvia.com
- IQVIA, GLP-1 Impact — GLP-1 adoption from 3% (2021) to >23% (2025) — iqvia.com
- Eli Lilly and Company, Q4 2025 financial results press release (SEC filing) — Mounjaro $23.0B and Zepbound $13.5B for full-year 2025 — lilly.gcs-web.com
- Novo Nordisk, Annual Report 2024 — Financials — GLP-1 portfolio revenue (Wegovy + Ozempic + Rybelsus) — annualreport.novonordisk.com
- Hims & Hers Health, Inc., Q4 2025 / Full Year 2025 earnings release (Form 8-K filed with SEC) — 2026 revenue guidance of $2.7B–$2.9B — sec.gov
- Wozny J.S., Truong C.N. et al., Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns, American Journal of Managed Care (AJMC) — peer-reviewed analysis of a US commercial claims database 2018–2023; GLP-1 RA users grew 745 → 3,572 per 100,000 enrollees; diabetic share of users fell 89% → 66% (non-diabetic share tripled from 11% to 34%) — ajmc.com
- IQVIA, Non-Traditional Channels: The Compounded GLP-1 Market (Oct 2025) — iqvia.com
Regulatory timeline and provider strategies
- FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — canonical FDA page covering tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortage delistings and 503A / 503B grace-period dates — fda.gov clarifies policies
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA's standing public statement on adverse-event reports from compounded versions, noting under-reporting because state-licensed pharmacies are not required to file with FAERS — fda.gov concerns
- FDA press release, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List (30 Apr 2026) — fda.gov press announcement
- Julia Belluz, Opinion: GLP-1 Experimentation Is Everywhere, and Science Can't Keep Up, The New York Times (15 Apr 2026) — aggregates FAERS adverse-event data through July 2025 (1,150+ events, 17 deaths) — nytimes.com
- STAT News, coverage of the Hims & Hers Q4 2025 earnings call (23 Feb 2026) — statnews.com
Provider descriptions on this page come from each provider's public site, accessed June 2026; specific URLs are listed inside each provider's full review.
Editorial independence We take no payment for coverage, placement or rankings, and we publish corrections. Editorial policy